Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L29 pseudogene 27 (RPL29P27) is a processed pseudogene of the human ribosomal protein L29 gene. It is annotated in genomic databases and may share sequence homology with RPL29, but does not produce a functional protein product and does not participate directly in biochemical pathways. There is currently no evidence of transcription, translation, or involvement in biological or disease processes for RPL29P27. Pseudogenes such as RPL29P27 are common in the genome and generally do not have therapeutic significance[7]. The functional gene, RPL29, encodes a ribosomal protein involved in protein synthesis; its pseudogenes like RPL29P27 do not fulfill this function and are not considered drug targets[1][5][7]. If structured target data are required for research, RPL29P27 should be annotated as a pseudogene and flagged as not being a canonical therapeutic target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L29 pseudogene 27 (RPL29P27).